Compare Elastic NV (ESTC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs McKesson Corporation — how do they compare? Elastic NV trades at $98.19 (market cap $10.00B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 10.8× Elastic NV's market cap, and McKesson Corporation pays a 0.4% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and McKesson Corporation for 74 Days on average.
| ESTC | MCK | |
|---|---|---|
Market Cap | $10.00B | $108.46B |
Volume | 1,610,337 | 712,607 |
Sector | Technology | Health |
52-Week High | $99.91 | $995.69 |
52-Week Low | $43.30 | $725.17 |
Typical Hold Time | 10 Days | 74 Days |
Enterprise Value | $9.14B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $97.54, up 4.77% on the day, reflecting strong momentum as it approaches resistance near $98. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though the short-term RSI indicates potential overbought conditions. Fundamentally, the company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, projected to rise from $1.48 billion in 2025 to $1.8 billion in 2026, while net income is expected to swing from a loss to a $376 million profit, signaling improving profitability. Recent news highlights product innovations in AI and observability platforms, reinforcing its competitive edge.
The outlook for ESTC is positive, driven by earnings beats, solid revenue expansion, and strategic product launches in high-growth areas like AI and data search. Key risks include high valuation multiples, such as a P/E of 27.22 and EV/EBITDA of 496.59, which may limit upside if growth slows. Analyst consensus is strongly bullish with a 64.71% buy rating, though the average price target of $79.50 suggests caution relative to the current price. Investors should weigh the strong fundamental trajectory against valuation concerns and market volatility.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
